Opus Genetics (IRD) Profit After Tax Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.93% |
| Dec 31, 2025 | 2.42% |
| Sep 30, 2025 | -69.49% |
| Jun 30, 2025 | -35.84% |
| Mar 31, 2025 | -21.55% |
| Dec 31, 2024 | -127.40% |
| Sep 30, 2024 | -30.89% |
| Jun 30, 2024 | -25.80% |
| Mar 31, 2024 | -24.84% |
| Dec 31, 2023 | -9.00% |
| Sep 30, 2023 | 24.92% |
| Jun 30, 2023 | -5.27% |
| Mar 31, 2023 | -22.79% |
| Dec 31, 2022 | 62.83% |
| Sep 30, 2022 | -34.27% |
| Jun 30, 2022 | -48.42% |
| Mar 31, 2022 | 21.13% |
| Dec 31, 2021 | -64.41% |
| Sep 30, 2021 | -8.09% |
| Jun 30, 2021 | -32.22% |
| Mar 31, 2021 | -56.55% |
| Dec 31, 2020 | -45.63% |
| Sep 30, 2020 | 20.89% |
| Jun 30, 2020 | 13.09% |
| Mar 31, 2020 | 6.28% |
| Dec 31, 2019 | 17.82% |
| Sep 30, 2019 | -0.56% |
| Jun 30, 2019 | -71.12% |
| Mar 31, 2019 | 30.64% |
| Dec 31, 2018 | -2.76% |
| Sep 30, 2018 | -20.05% |
| Jun 30, 2018 | -4.31% |
| Mar 31, 2018 | -6.28% |
| Dec 31, 2017 | -130.34% |
| Sep 30, 2017 | 19.06% |
| Jun 30, 2017 | 23.80% |
| Mar 31, 2017 | -58.80% |
| Dec 31, 2016 | -27.35% |
| Sep 30, 2016 | -14.31% |
| Jun 30, 2016 | 21.25% |
| Mar 31, 2016 | 1.33% |
| Dec 31, 2015 | -1.79% |
| Sep 30, 2015 | -82.77% |
| Jun 30, 2015 | 2.10% |